BeOne Medicines Ltd Share Price Today: Live Updates & Key Insights
BeOne Medicines Ltd share price today is $275.28, up -2.63%. The stock opened at $284 against the previous close of $282.72, with an intraday high of $284.45 and low of $275.02.
BeOne Medicines Ltd Share Price Chart
BeOne Medicines Ltd
BeOne Medicines Ltd Share Price Performance
BeOne Medicines Ltd Institutional Holdings
BeOne Medicines Ltd Market Status
BeOne Medicines Ltd Fundamentals
Market Cap 31617.42 M
PB Ratio 7.1957
PE Ratio 111.0
Enterprise Value 29186.00 M
Total Assets 8188.57 M
Volume 226610
BeOne Medicines Ltd Company Financials
About BeOne Medicines Ltd & investment objective
Company Information BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.
Organisation Biotechnology
Employees 12000
Industry Biotechnology
CEO Mr. John V. Oyler
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:
Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*
Take your next step
BeOne Medicines Ltd FAQs
What is the share price of BeOne Medicines Ltd today?
The current share price of BeOne Medicines Ltd is $275.28.
Can I buy BeOne Medicines Ltd shares in India?
Yes, Indian investors can buy BeOne Medicines Ltd shares by opening an international trading and demat account with Motilal Oswal.
How to buy BeOne Medicines Ltd shares in India?
You can easily invest in BeOne Medicines Ltd shares from India by:
- Direct Investment:
Opening an international trading account with Motilal Oswal which includes KYC verification in the US. Your account gets activated in a few minutes to a few hours, after which you can start adding funds in USD balance to buy BeOne Medicines Ltd shares. - Indirect Investment:
Under this form of investment, you can choose either a Mutual Fund (MF) or an Exchange-Traded Fund (ETF) that invests in global shares and start investing in shares of BeOne Medicines Ltd.
Can I buy fractional shares of BeOne Medicines Ltd?
Yes, many platforms allow you to buy fractional shares starting from as low as $1.
What is the market capitalization value of BeOne Medicines Ltd?
BeOne Medicines Ltd has a market cap of $31617.42 M.
In which sector does BeOne Medicines Ltd belong?
BeOne Medicines Ltd operates in the Biotechnology sector.
What documents are required to invest in BeOne Medicines Ltd stocks?
To invest, you typically need:
What is the PE and PB ratio of BeOne Medicines Ltd?
The PE ratio of BeOne Medicines Ltd is 111.00 and the PB ratio is 7.20.